After a positive phase I dose escalation and expansion study of this medication in patients with previously treated IDH1-mutant advanced CC, this drug was further tested in a phase III randomized trial (ClarIDHy) [57,58]. The gene discussed is IDH1; the disease is cholangiocarcinoma.